Please assess the completion status of the following clinical trial:

Trial Title: Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-infectious uveitis (pan, anterior, intermediate and posterior)~* Diagnosis of macular edema associated with non-infectious uveitis (retinal thickness ≥ 300 microns)~* Visual Acuity score of ≥ 5 letters read (20/800 Snellen equivalent) and ≤ 70 letters read (20/40 Snellen equivalent), in the study eye~Exclusion Criteria:~* Any active ocular disease or infection in the study eye other than uveitis~* Intraocular pressure \> 22 mmHg or uncontrolled glaucoma in the study eye; subjects are not excluded if IOP ≤ 22 mmHg with no more than 2 IOP lowering medications.~* Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study~* Any topical ocular corticosteroid in the 10 days prior to baseline; intraocular or periocular corticosteroid injections in the 2 months prior to baseline; an OZURDEX implant in the 6 months prior to baseline; RETISERT or ILUVIEN implant in the 3 years prior to baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4mg CLS-TA Suprachoriodal Injection (Type: EXPERIMENTAL): Suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
- Sham Procedure (Type: SHAM_COMPARATOR): Matching suprachoroidal syringe with sham procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).